VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2016

Mar 18, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2016-03-16

Reporting Person: BOGER JOSHUA S (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-03-16	Common Stock	M	5130	$35.35	Acquired	270414	Direct
2016-03-16	Common Stock	S	1300	$78.07	Disposed	269114	Direct
2016-03-16	Common Stock	S	1533	$79.00	Disposed	267581	Direct
2016-03-16	Common Stock	S	1197	$79.98	Disposed	266384	Direct
2016-03-16	Common Stock	S	300	$81.00	Disposed	266084	Direct
2016-03-16	Common Stock	S	600	$82.27	Disposed	265484	Direct
2016-03-16	Common Stock	S	200	$82.98	Disposed	265284	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-03-16	Stock Option (Right to Buy)	$35.35	M	5130	Disposed	2016-07-19	Common Stock (5130)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	13286	Indirect
Common Stock	122700	Indirect

Footnotes

F1: Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1.

F2: Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F3: Open market sales reported on this line occurred at a weighted average price of $78.07 (range $77.71 to $78.62).

F4: Open market sales reported on this line occurred at a weighted average price of $79.00 (range $78.73 to $79.45).

F5: Open market sales reported on this line occurred at a weighted average price of $79.98 (range $79.74 to $80.31).

F6: Open market sales reported on this line occurred at a weighted average price of $81.00 (range $80.92 to $81.12).

F7: Open market sales reported on this line occurred at a weighted average price of $82.27 (range $81.94 to $82.79).

F8: Fully vested.